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Purpose: To assess the safety and usefulness of neutron brachytherapy (NBT) as an adjuvant in the treatment of
patients with gastroesophageal junction adenocarcinoma (GEJAC) with external beam radiation (EBRT), with or
without chemotherapy.
Methods and Materials: In total, 197 patients with localized, advanced GEJAC received EBRT and NBT with or
without chemotherapy. Radiotherapy consisted of external irradiation to a total dose of 40–54 Gy (median 50 Gy) and
brachytherapy to 8–25 Gy (median 20 Gy) in two to five fractions. In total, 88 patients received chemotherapy that
consisted of two cycles of a regimen with CDDP and 5FU from days l-4. The cycles were administered on days 1 and
29. MMC was given alone in bolus injection on day 1 each week. The cycles were administered on days 1, 8, 15 and 22.
Results: The duration of follow-up ranged from six to 106 months (median 30.4 months). The median survival
time for the 197 patients was 13.3 months, and the one, two, three- and five-year rates for overall survival were
57.1%, 35.1%, 23.0% and 9.2%, respectively. For acute toxicity, no incidences of fistula and massive bleeding were
observed during this treatment period. In total, 159 (80.7%) patients developed Grade 2 hematologic toxicity and
146 (74.1%) patients developed Grade ≥ 2 esophagitis. The median times of incidence of fistula and bleeding
were 9.5 (3–27.3) months and 12.7 (5–43.4) months, respectively. The incidence of severe, late complications was
related to higher NBT dose/f (20–25 Gy/5 F) and higher total dose(≥70 Gy). In total, 75.2% of the patients resumed
normal swallowing and 2.0% had some residual dysphagia (non-malignant) requiring intermittent dilatation.
Conclusion: A combination of EBRT and NBT with the balloon type applicator was feasible and well tolerated. Better
local-regional control and overall survival cannot achieved by a higher dose, and in contrast, a higher dose caused
more severe esophageal injury.
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Table 1 Patient/tumor characteristics
Characteristics Total (%) CRT (%) RT (%) p Value
Sex 0.008
Male 153 (77.7) 76 (86.4) 77 (70.6)
Female 44 (22.3) 12 (13.6) 32 (29.4)
Age (years) 0.028
≤65 73 (37.3) 40 (45.5) 33 (30.3)
>65 124 (62.7) 48 (54.5) 76 (69.7)
KPS 0.141
≥80 114 (57.9) 56 (63.6) 58 (53.2)
70 83 (42.1) 32 (36.4) 51 (46.8)
The length 0.358
≤5 cm 182 (92.4) 83 (94.3) 99 (90.8)
>5 cm 15 (7.6) 5 (5.7) 10 (9.2)
Tumor location 0.092
Type I 9 (4.6) 4 (4.5) 5 (4.6)
Type II 95 (48.2) 35 (36.8) 60 (55.0)
Type III 93 (47.2) 49 (55.7) 44 (40.4)
T stage 0.002
T2 36 (18.3) 8 (9.1) 28 (25.7)
T3 68 (34.5) 31 (35.2) 37 (33.9)
T4 93 (47.2) 49 (55.7) 44 (40.4)
N stage <0.0001
N0 49 (24.9) 9 (10.2) 40 (36.7)
N1 148 (75.1) 79 (89.8) 69 (63.3)
6th AJCC stage <0.0001
II 46 (23.4) 9 (10.2) 37 (33.9)
III 151 (76.6) 79 (89.8) 72 (66.1)
Total dose 0.235
≤70 67 (34.0) 26 (29.5) 41 (37.6%)
>70 130 (66.0) 62 (70.5) 68 (62.4)
Abbreviations: CRT chemotherapy plus radiotherapy, Total dose EBRT + NBT
dose, OS Overall survival rate, LRC Local-regional control.
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Tumors of the lower esophagus and the proximal stomach
are usually classified as gastroesophageal junction adeno-
carcinomas (GEJAC). These carcinomas are the most rap-
idly increasing type of tumor in many Western countries,
and they represent an aggressive disease with poor progno-
sis [1,2]. With the present state of knowledge, some pa-
tients with localized GEJ cancers are treated with surgery
alone; others with chemotherapy pre- and postoperatively;
and some with trimodality therapy, either preoperatively or
postoperatively. The choice of treatment mostly depends
on the preferences of the treating team of physicians.
The nonsurgical management of patients with GEJAC,
including the use of laser coagulation or self-expanding
metallic stents with radiation, has been considered for
decades to only be a palliative modality. However, for pa-
tients with inoperable GEJAC or those who have rejected
an operation, there has yet to be any studies on the
safety and usefulness of neutron brachytherapy (NBT)
in their treatment.
Californium-252 (252Cf) is a neutron-emitting radio-
nuclide, and 252Cf-based NBT has only been implemented
in China very recently [3]. NBT is a form of high linear en-
ergy transfer (LET) radiotherapy, which has been proven to
be effective for treating intracavitary cancers of the cervix
when used in combination with external beam radiotherapy
(EBRT) [4,5]. However, no studies regarding the treatment
of GEJAC by EBRT combined with NBT have been re-
ported. NBT is thought to be a viable option for treating
GEJAC for at least three reasons. First, GEJAC is resistant
to the conventional, low-LET X-ray or gamma-ray radio-
therapy [6]. NBT is a form of high-LET radiotherapy,
which has been shown to be effective in killing radio-
resistant cancer cells [5,7]. Second, the location of
GEJAC makes it easily accessible to the 252Cf neutron
source via the use of an applicator/catheter. Third, water
is an effective neutron shield, and it can be injected into
the source applicator during treatment to reduce the
neutron dose to the normal tissue near the tumor.
The aim of the present study was to observe and
analyze the long-term curative effects and complications
of NBT as an adjuvant in the treatment of patients with
GEJAC with EBRT with or without chemotherapy.
Materials and methods
Patients
From Jan 2001 until November 2012, a total of 197 con-
secutive patients with localized, advanced gastroesophageal
cancer were referred to our department at the Changzhi
Cancer Hospital for radiotherapy and 252Cf NBT. The
reasons were as follows: 10 patients were medically in-
operable; 40 rejected surgery; 83 were too old (71 years
or older, 34 of 83 had T4 lesion); 93 had unresectable
lesions and one had other malignancy. Of these 197patients, 88 were treated with chemoradiotherapy com-
bined with brachytherapy (the CRT group). Patients with
good performance status (at least able to care for himself
or herself ) and adequate hepatic, renal, and hematologic
functions were selected for curative treatment. All of the
patients had adenocarcinoma. The patients’ 6th AJCC
stages were diagnosed to be Stage II to III by barium
examination, endoscopy, endoscopic ultrasonography or
tumor histology. The classification of GEJAC was divided
into Type I to Type III [8]. All of the patients gave their
informed consent before treatment, which was in accord-
ance with the Declaration of Helsinki and also approved
by the Ethics Committee of Changzhi Cancer Hospital.
The demographic data and tumor characteristics of each
group are given in Table 1.
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Megavoltage radiation therapy units were used with a
minimum source-to-axis distance of 100 cm. The radi-
ation field extended at least 3 cm superior and inferior
to the tumor, with a lateral margin of at least 2 cm. The
field included the lesser curvature and bottom of stom-
ach if the tumor was type III. The boost radiation field
was the same length. Multi-field techniques were used
to limit the maximum dose to the spinal cord to ≤45 Gy.
The radiation treatments were delivered five days/week
and at 2 Gy/fraction. The initial anterior-posterior parallel-
opposed fields received 30 Gy and the off-cord fields re-
ceived 20–30 Gy, for a total dose of 40–54 Gy in 20–27
fractions in 4–5.5 weeks.
NBT with a one-balloon applicator (Figure 1) was used
in conjunction with the 252Cf LZH-1000 remote after-
loading system (Linden Science and Technology Co,
Shenzhen, China). The physical characteristics of 252Cf
Neutron, the characteristics of the applicator and the
process of NBT were described in detail by Liu H [9].
The dose was prescribed to the reference point, which
was located at 10 mm from the center point of the
source capsule in the transverse direction. Figure 1 is an
X-ray image taken while the applicator and the source
were both inserted into the esophagus of a patient. In
Figure 1, the water balloon can clearly be seen as it is
filled with an X-ray contrast agent. The dose was pre-
scribed to the reference point, which located 10 mm from
the center point of the source capsule in the transverse
direction. The total radiation dose (to the reference point)
given to each patient varied between 8–25 Gy-eq in two
to five fractions, with 4–5 Gy-eq per fraction per week.
Chemotherapy
Chemotherapy consisted of three cycles of a regimen
with CDDP (20 mg/m2/d in 2 h infusion) and 5FU
(500 mg/m2/d in continuous infusion) from days l-4.Figure 1 An X-ray image was taken while the applicator and the sour
balloon can clearly be seen as it is filled with an X-ray contrast agent. The
from the center point of the source capsule in the transverse direction. FromThe cycles were administered on days 1 and 29. MMC
was given alone in a bolus injection on day 1 per week
at 4 mg/m2. The cycles were administered on days 1,
8,15 and 22.Toxicity assessment and follow-up
The patients were examined weekly during the course
of external beam radiation. Weekly blood tests were
obtained, and any admission for treatment-related
complications was recorded. All adverse events were
graded according to the National Cancer Institutes
Common Terminology Criteria for Adverse Events,
version 3.0 [10].
The patients usually underwent follow-up examinations
every 3–4 months after the completion of treatment.
Tumor response and nodal disease were evaluated with re-
peated CT scans, barium swallow studies and endoscopy.Statistical analysis
The objectives of the study were to evaluate overall
acute toxicity and local-regional control rates. Death
from esophageal cancer was considered as treatment
failure in the survival analysis. Survival was calculated
from the date of consultation until death or last follow-
up evaluation. The pattern of failure (local and/or re-
gional vs. distant) was defined as the first site of failure.
The time to first failure, time to any local failure and
time to any distant metastases were calculated from the
date of consultation. Local and regional recurrence in-
cluded the primary tumor and regional lymph nodes.
Overall survival and local-regional control were esti-
mated using the Kaplan–Meier method. Pearson’s chi-
square test was used to assess measures of association in
the frequency data. A value of p<0.05 was considered
statistically significant.ce were both inserted into the esophagus of a patient. The water
dose was prescribed to the reference point, which was located 10 mm
the first to fourth NBT, the shape of the tumor can be clearly identified.
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Patients’ characteristics and treatments
The ages of the esophageal cancer patients who were
treated with radiation therapy (NBT and EBRT) ranged
from 44 to 84 years (median, 69 years). The tumor stage
was distributed as follows for the 197 patients: II (n = 46)
and III (n =151) by 6th AJCC tumor stage. All patients
completed the planned EBRT +NBT treatment. Among
these patients, 88 patient received CRT, of which 25 and
63 patients received the PF and MMC alone regimens,
respectively. The patients’ characteristics and treatments
are summarized in Table 1.
Prognostic factors for overall survival and local-regional
control
The duration of follow-up ranged from six to 106 months
(median 30.4 months). The median survival time for the
197 patients was 13.3 months, and the one-, two-, three-
and five-year rates for OS were 57.1%, 35.1%, 23.0% and
9.2%, respectively. The one-, two-, three- and five-year
rates for LRC were 76.6%, 61.5%, 50.1% and 35.9%,
respectively.
We used the nine following factors for the univariate
analysis of survival rates and local control rate: sex, age,
tumor location, tumor length, tumor T stage, nodal stage,
clinical stage, concurrent chemotherapy, and radiation
dose. We found that clinical stage was the only factor
that was significantly related to OS and LRC (Figure 2,
p = 0.017 and p = 0.019, respectively). In the univariate
analysis, the five-year OS (LRC) was 15.3% (50.1%) and
7.0% (30.2%) for stage II and III group patients, respect-
ively (p = 0.017, p = 0.019). We did not observe that
the CRT regimen and increasing the total dose was able
to significantly increase the OS and LRC of patients.
Patterns of failure
At the time of the analysis, 28 patients were alive and
free of disease and five patients were alive with disease
evolution. Distant metastases occurred in 40 patientsFigure 2 Comparison of overall survival (OS, A) and local-regional
Statistically significant differences were found in LRC and OS, which fav(20.3%). The median time to developing distant metasta-
ses was 13.3 months. The main sites of distant metasta-
ses were the lung (n = 13), liver (n = 5), brain (n = 4) and
bone(n = 4). In 14 patients, metastases developed in
more than one organ. Two patients developed second
primary tumors. Additionally, 37 patients died of mixed
reasons, including pneumonia, cerebral hemorrhage,
heart infarction and a car accident. Local-regional recur-
rence occurred in 76 (76/197,38.6%) patients, with 44/76
(57.9%) occurrences outside the radiation fields and 58/76
(76.3%) occurrences inside the radiation fields. Additionally,
26/76 (34.2%) had both inside and outside filed recurrences.
None of those patients underwent salvage surgery.
Treatment toxicity
All 197 patients completed the planned NBT and EBRT
treatment. In terms of acute toxicity, no perforations
were observed during this treatment period. In total, 159
(80.7%) patients developed a Grade 2 hematologic tox-
icity. Dysphagia was relieved after the second or third
NBT treatment in 95% of the patients, and a temporary
feeding tube was not required in most of the patients.
Grade ≥ 2 esophagitis, expressed by clinical odynophagia,
was observed in 146 cases (74.1%) and was managed
with the early introduction of H2 blockers and surface
anesthesia at the initiation of the NBT. In total, 12 pa-
tients had Grade ≥ 2 irradiation dermatitis. From the
time of treatment completion to the development of
local-regional recurrence or death at the follow time, 8
(4.1%) and 13 (6.6%) patients experienced fistula and
massive bleeding, respectively. The median time of inci-
dence of fistula and bleeding was 9.5(3–27.3) months
and 12.7(5–43.4) months, respectively. As shown in Table 2,
the incidence of severe, late complications was related to
higher NBT dose/f (20–25 Gy/5 F) and higher total dose
(≥70 Gy). In total, 75.2% of the patients resumed normal
swallowing, while 2.0% had some residual dysphagia
(non-malignant) requiring intermittent dilatation. For
acute toxicity, CRT increased the incidence of Grade ≥ 2control (LRC, B) between patients with different clinical stages.
ored stage II patients.
Table 2 shows the relationship between NBT and EBRT
dose factor and severe complications
Factors Fistula Bleeding
CRT Yes 4 4
No 4 9
NBT dose/F 12 Gy/3 F 2 1
16 Gy/4 F 1 2
20 Gy/5 F 4 7
25 Gy/5 F 1 3
EBRT 40 Gy 2 2
50 Gy 6 9
52 Gy 1
60 Gy 1
Total dose 52-56 Gy 2 1
60-66 Gy 1 2
70-75 Gy 5 10
Note: CRT = chemotherapy plus radiotherapy, Total dose = EBRT + NBT dose.
F = fraction, NBT = neutron brachytherapy, EBRT = external beam radiotherapy.
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Other acute toxicities and late complications did not
have any significant relationship to higher total dose
and receiving the CRT regimen.
Discussion
Preoperative chemotherapy and preoperative chemora-
diotherapy followed by surgery are well established in
the curative treatment of patients with localized GEJAC
[11,12]. However, for patients with locally advanced,
non-resectable and inoperable GEJAC, palliative therapy,
including the use of intraluminal stents, photodynamic
therapy, brachytherapy and argon plasma coagulation
[13], is the main choice. The use of stents has changed
clinical practice in patients with critical dysphagia [14],
and a recent trial supports the continued use of palliative
radiotherapy, as it confers benefits on patient survival and
quality of life. There is randomized trial evidence that
single dose, intraluminal brachytherapy provides better
long-term relief of dysphagia with improved quality of
life than stents but requires a longer time to symptom-
atic relief [15]. However, a few studies have reported
the safety and inefficacy of external radiotherapy and
brachytherapy as a curative treatment for GEJAC. We
retrospectively analyzed our database and found that
first, using NBT as an adjuvant in the treatment of pa-
tients with GEJAC with EBRT with or without chemo-
therapy is well tolerated and useful. Second, improving
the total dose and combining it with chemotherapy
does not result in better OS and LRC and also causes a
higher incidence of late, severe complications. Third,
for patients with stage II, this treatment can result in
improved OS.Prior to this report, the number of studies using EBRT
and BT to boost concurrent chemotherapy in a mean-
ingful number of patients have been limited [16]. Table 3
summarizes these experiences, as well as our own. The
present study shows survival benefits for addition of NBT
to EBRT for treating locally advanced disease, resulting
in a median overall survival time of 13.3 months, as
Hishikawa et al. [17] and Hareyama et al. [18] have pre-
viously reported.
The optimal dose for using BT as an adjuvant is un-
known, but the incidence of late complications has been
related to the dose to the mucosa [19], dose per fraction
[20,21], dose rate [22] and chemotherapy [23]. Sur et al.
[24] observed a difference in the local control that
depended on whether the boost was delivered with
20 Gy or 12 Gy HDRBT after an initial 35 Gy EBRT. At
one year, the local control was, 25% and 70.6%, respect-
ively. In the present study, the boost dose in patients
varied from 20 Gy to 25 Gy, with the total dose being
less than 70 Gy. These doses did not significantly pro-
long the patients’ OS or improve their LRC. Addition-
ally, for GEJAC, blindly increasing the RT dose did not
increase the OS and LRC, and further research should
include studies on the reasonable dosage scope or the
combination with other treatments, such as chemother-
apy or targeted therapy, to improve curative effect.
The risk of late complications seems to be strongly af-
fected by a higher dose and a large fraction size of HDR
BT [16,25]. Sharma compared the treatment-related
complications in groups 1 (20 Gy BT boost) and 2 (15 Gy
BT boost) and reported strictures in 24% vs. 8% (p = 0.029),
respectively, ulceration in 30% vs. 28% (p = 0.8), respect-
ively, and tracheoesophageal fistulae in 12% of patients in
both groups [25]. A high incidence of esophageal fistulas
(8%) was reported in the RTOG 9207 study [16]. In this
study, a dose of 8–25 Gy in 2–5 fractions via HDR NBT
was delivered. Our study also demonstrated that 21 pa-
tients treated with EBRT and NBT developed severe, late
toxicity. The incidence of late, severe complications was
significantly related to higher total dose and NBT dose fac-
tors. In addition to dose factors, the combined treatment
with chemotherapy also significantly increased the inci-
dence of relevant, late complications. Atsunori Yorozu re-
ported that treatment-related esophageal ulceration or
strictures occurred in 18 patients (34%) in the CRT group,
compared with 12% in the RT group (p = 0.013) [26].
RTOG 9207 [16] documented treatment-related esopha-
geal fistulas in 12% of the patients. In comparison, none
were reported in several other BT and EBRT without CT
series [17,18,23,27]. The present study has documented no
acute fistulas of the patients, compared to the reports by
Hishikawa et al. [17] or Gava et al. [27]. However, the direct
comparison of these clinical series is hampered by the dif-
ferences in staging, classification, response end points and
Table 3 Clinical results of external beam radiation, brachytherapy boost, with or without chemotherapy
Authors (Ref.) Hishikawa et al. [17] Flores et al. [23] Hareyama et al. [18] Sharma et al. [25] RTOG9207 [16] Present study*
No. of pts. 148 171 161 100 50 197
BT Gy/fraction 12/1 15/1 15-20/NS 15-20/1 15/3 12-25/2-6
EBRTGy/fraction 60/30 40/15 47-70/25-35 50/28 50 30-60
CT (pts) No No No Yes Yes 88/197
Fistula (%) 5.3 5 1.2 12 12 8 (4.1%)
Bleeding (%) 0% 11 0 4 NS 13 (6.6%)
Ulcer (%) NS NS 3 29 NS NS
Stricture (%) 10 35 3 16 4 4 (2%)
Death rate (%) 3 0.6 0 4 8 0
OS (%) 37 (2 y) LD 33 (1 y) 43.3/Stage I, 8 (20 Gy) 49 (1 y) 57.1 (1 y)
8 (2 y) ED 26 (2 y) 21.1/Stage II, 23 (15 Gy) 35.1 (2 y)
19 (3 y) (5 y) (5 y) 9.2 (5 y)
LRC (%) 64 (2 y) LD NS 31.7%(5 y) NS 35.9 (5 y)
Abbreviations: CT Chemotherapy, HDR high dose rate, NS not stated, LD limited disease, ED extensive disease, y year.
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with or without CT resulted in treatment complication
similar to that which has been reported [17,18,23,25,27].
Because 252Cf NBT is a form of high-LET radiotherapy, we
believe that it is superior to conventional X-ray radiother-
apy in treating radio-resistant esophageal cancers. An add-
itional advantage of NBT over X-ray radiotherapy is the
fact that water can be injected into the source applicator
during treatment to reduce the neutron dose to nearby
normal tissue. RTOG 9207 [16] reported that increased
courses of chemotherapy and chemotherapy concurrent
with brachytherapy may significantly improve the incidence
of late, severe complications. In the present study, the inci-
dence of severe, late complications in the CRT group was
similar to that in the RTalone group. This can be explained
by several main reasons. Firstly, the chemotherapy regi-
mens were multifarious, with most of the patients receiving
the MMC alone regimen. Secondly, the concurrent
chemotherapy doses were lower than those used in nor-
mal chemotherapy alone regimens and may have resulted
in radiotherapy sensitization. Thirdly, neutron irradiation
overcomes the radiation resistance of the tumor, thus
reducing the chemotherapy sensitization effect.
Conclusion
In summary, NBT + EBRT is a highly effective and well-
tolerated therapeutic modality, which can be used not
only as a palliative therapy but also as a radical treat-
ment for patients with inoperable GEJAC. Statistically
significant better LRC and OS were observed in patients
with stage II disease. Increasing the total dose and com-
bining it with chemotherapy did not improve OS and
LRC and resulted in a higher incidence of late, severe
complications. However, the accuracy of the data on
toxicity was limited by the retrospective nature of thisstudy. Methods to reduce treatment toxicity and increase
the tumor response to radiotherapy, thereby increasing
the therapeutic ratio, are needed. Our data indicate a need
for additional studies on the optimal EBRT and NBT dose
in a prospective randomized trial. In particular, the studies
should place emphasis on decreasing the treatment-
related toxicity of concurrent chemoradiotherapy, as it
is the only treatment modality available for patients
with locally advanced GEJAC.
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